Systemic lupus erythematosus (SLE) is a complex autoimmune disease that can affect nearly any organ or system in the body. As a result, its course, manifestations, and treatment approach can be highly variable between patients. This lack of consistency has made clinical trial design, as well as understanding the potential market for therapies in SLE, a unique challenge. To date, GlaxoSmithKline’s Benlysta (2011) is the only drug to have launched for SLE in over 50 years; however, its modest efficacy is a deterrent to uptake. GlaxoSmithKline’s Benlysta and Aurinia’s Lupkynis (voclosporin) have recently been granted FDA approval for the treatment of adult patients with active LN. Several therapies (i.e., anifrolumab, baricitinib, dapirolizumab pegol, voclosporin, obinutuzumab) in development for moderate to severe SLE without active renal disease and/or lupus nephritis are expected to fulfill the high unmet need for this condition. The Disease Landscape and Forecast provides detailed analyses of current medical practice, key unmet needs, and new developments in the SLE space, along with an analysis of opportunities and obstacles facing emerging agents.
Questions answered:
Scope:
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: Approximately 32 country-specific interviews with rheumatologists and nephrologists.
Epidemiology: Diagnosed prevalence of SLE by country and subpopulations (nonrenal SLE and LN).
Population segments in market forecast: Total population, nonrenal SLE population, renal SLE (LN) population.
Emerging therapies: Phase II: 19 drugs; Phase III: 6 drugs.